Microfluidic Point-of-Care Ecarin-Based Clotting and Chromogenic Assays for Monitoring Direct Thrombin Inhibitors

Benjamin Alouidor, Robin E. Sweeney, Trinny Tat, Raymond K Wong, Jeong-Yeol Yoon

Research output: Contribution to journalArticle

Abstract

Direct thrombin inhibitors (DTIs), such as bivalirudin and dabigatran, have maintained steady inpatient and outpatient use as substitutes for heparin and warfarin, respectively, because of their high bioavailability and relatively safe "on-therapy" range. Current clinical methods lack the capacity to directly quantify plasma DTI concentrations across wide ranges. At present, the gold standard is the ecarin clotting time (ECT), where ecarin maximizes thrombin activity and clotting time is evaluated to assess DTIs' anticoagulation capability. This work focused on the development of a microfluidic paper analytic device (µPAD) that can quantify the extent of anticoagulation as well as DTI concentration within a patient's whole blood sample. Capillary action propels a small blood sample to flow through the nitrocellulose paper channels. Digital images of whole blood migration are then captured by our self-coded Raspberry Pi and/or the Samsung Galaxy S8 smartphone camera. Both the flow length and the blue absorbance from the plasma front on the μPAD were measured, allowing simultaneous, dual assays: ecarin clotting test (ECT) and ecarin chromogenic assay (ECA). Statistically significant (p < .05) changes in flow and absorbance were observed within our translational research study. Currently, there are no quantitative, commercially available point-of-care tests for the ECT and ECA within the United States. Both the ECT and ECA assays could be instrumental to differentiate between supratherapeutic and subtherapeutic incidents during bridging anticoagulant therapy and limit the unwarranted use of reversal agents.

Original languageEnglish (US)
Pages (from-to)29-37
Number of pages9
JournalThe journal of extra-corporeal technology
Volume51
Issue number1
StatePublished - Mar 1 2019

Fingerprint

Point-of-Care Systems
Microfluidics
Antithrombins
Galaxies
Capillary Action
Equipment and Supplies
Translational Medical Research
Collodion
ecarin
Warfarin
Thrombin
Anticoagulants
Biological Availability
Heparin
Inpatients
Outpatients

Keywords

  • bivalirudin
  • dabigatran
  • DTI
  • ecarin chromogenic assay
  • ecarin clotting time
  • paper microfluidics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Microfluidic Point-of-Care Ecarin-Based Clotting and Chromogenic Assays for Monitoring Direct Thrombin Inhibitors. / Alouidor, Benjamin; Sweeney, Robin E.; Tat, Trinny; Wong, Raymond K; Yoon, Jeong-Yeol.

In: The journal of extra-corporeal technology, Vol. 51, No. 1, 01.03.2019, p. 29-37.

Research output: Contribution to journalArticle

@article{34ac9ac19ed74a0e95637a916ae0829e,
title = "Microfluidic Point-of-Care Ecarin-Based Clotting and Chromogenic Assays for Monitoring Direct Thrombin Inhibitors",
abstract = "Direct thrombin inhibitors (DTIs), such as bivalirudin and dabigatran, have maintained steady inpatient and outpatient use as substitutes for heparin and warfarin, respectively, because of their high bioavailability and relatively safe {"}on-therapy{"} range. Current clinical methods lack the capacity to directly quantify plasma DTI concentrations across wide ranges. At present, the gold standard is the ecarin clotting time (ECT), where ecarin maximizes thrombin activity and clotting time is evaluated to assess DTIs' anticoagulation capability. This work focused on the development of a microfluidic paper analytic device (µPAD) that can quantify the extent of anticoagulation as well as DTI concentration within a patient's whole blood sample. Capillary action propels a small blood sample to flow through the nitrocellulose paper channels. Digital images of whole blood migration are then captured by our self-coded Raspberry Pi and/or the Samsung Galaxy S8 smartphone camera. Both the flow length and the blue absorbance from the plasma front on the μPAD were measured, allowing simultaneous, dual assays: ecarin clotting test (ECT) and ecarin chromogenic assay (ECA). Statistically significant (p < .05) changes in flow and absorbance were observed within our translational research study. Currently, there are no quantitative, commercially available point-of-care tests for the ECT and ECA within the United States. Both the ECT and ECA assays could be instrumental to differentiate between supratherapeutic and subtherapeutic incidents during bridging anticoagulant therapy and limit the unwarranted use of reversal agents.",
keywords = "bivalirudin, dabigatran, DTI, ecarin chromogenic assay, ecarin clotting time, paper microfluidics",
author = "Benjamin Alouidor and Sweeney, {Robin E.} and Trinny Tat and Wong, {Raymond K} and Jeong-Yeol Yoon",
year = "2019",
month = "3",
day = "1",
language = "English (US)",
volume = "51",
pages = "29--37",
journal = "Journal of Extra-Corporeal Technology",
issn = "0022-1058",
publisher = "American Society of Extra-Corporeal Technology",
number = "1",

}

TY - JOUR

T1 - Microfluidic Point-of-Care Ecarin-Based Clotting and Chromogenic Assays for Monitoring Direct Thrombin Inhibitors

AU - Alouidor, Benjamin

AU - Sweeney, Robin E.

AU - Tat, Trinny

AU - Wong, Raymond K

AU - Yoon, Jeong-Yeol

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Direct thrombin inhibitors (DTIs), such as bivalirudin and dabigatran, have maintained steady inpatient and outpatient use as substitutes for heparin and warfarin, respectively, because of their high bioavailability and relatively safe "on-therapy" range. Current clinical methods lack the capacity to directly quantify plasma DTI concentrations across wide ranges. At present, the gold standard is the ecarin clotting time (ECT), where ecarin maximizes thrombin activity and clotting time is evaluated to assess DTIs' anticoagulation capability. This work focused on the development of a microfluidic paper analytic device (µPAD) that can quantify the extent of anticoagulation as well as DTI concentration within a patient's whole blood sample. Capillary action propels a small blood sample to flow through the nitrocellulose paper channels. Digital images of whole blood migration are then captured by our self-coded Raspberry Pi and/or the Samsung Galaxy S8 smartphone camera. Both the flow length and the blue absorbance from the plasma front on the μPAD were measured, allowing simultaneous, dual assays: ecarin clotting test (ECT) and ecarin chromogenic assay (ECA). Statistically significant (p < .05) changes in flow and absorbance were observed within our translational research study. Currently, there are no quantitative, commercially available point-of-care tests for the ECT and ECA within the United States. Both the ECT and ECA assays could be instrumental to differentiate between supratherapeutic and subtherapeutic incidents during bridging anticoagulant therapy and limit the unwarranted use of reversal agents.

AB - Direct thrombin inhibitors (DTIs), such as bivalirudin and dabigatran, have maintained steady inpatient and outpatient use as substitutes for heparin and warfarin, respectively, because of their high bioavailability and relatively safe "on-therapy" range. Current clinical methods lack the capacity to directly quantify plasma DTI concentrations across wide ranges. At present, the gold standard is the ecarin clotting time (ECT), where ecarin maximizes thrombin activity and clotting time is evaluated to assess DTIs' anticoagulation capability. This work focused on the development of a microfluidic paper analytic device (µPAD) that can quantify the extent of anticoagulation as well as DTI concentration within a patient's whole blood sample. Capillary action propels a small blood sample to flow through the nitrocellulose paper channels. Digital images of whole blood migration are then captured by our self-coded Raspberry Pi and/or the Samsung Galaxy S8 smartphone camera. Both the flow length and the blue absorbance from the plasma front on the μPAD were measured, allowing simultaneous, dual assays: ecarin clotting test (ECT) and ecarin chromogenic assay (ECA). Statistically significant (p < .05) changes in flow and absorbance were observed within our translational research study. Currently, there are no quantitative, commercially available point-of-care tests for the ECT and ECA within the United States. Both the ECT and ECA assays could be instrumental to differentiate between supratherapeutic and subtherapeutic incidents during bridging anticoagulant therapy and limit the unwarranted use of reversal agents.

KW - bivalirudin

KW - dabigatran

KW - DTI

KW - ecarin chromogenic assay

KW - ecarin clotting time

KW - paper microfluidics

UR - http://www.scopus.com/inward/record.url?scp=85064214280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064214280&partnerID=8YFLogxK

M3 - Article

VL - 51

SP - 29

EP - 37

JO - Journal of Extra-Corporeal Technology

JF - Journal of Extra-Corporeal Technology

SN - 0022-1058

IS - 1

ER -